804 related articles for article (PubMed ID: 30174217)
1. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
3. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
4. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
[TBL] [Abstract][Full Text] [Related]
6. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
Nawaf MG; Ulvmar MH; Withers DR; McConnell FM; Gaspal FM; Webb GJ; Jones ND; Yagita H; Allison JP; Lane PJL
J Immunol; 2017 Aug; 199(3):974-981. PubMed ID: 28646041
[TBL] [Abstract][Full Text] [Related]
7. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self.
Miska J; Bas E; Devarajan P; Chen Z
Eur J Immunol; 2012 Oct; 42(10):2584-96. PubMed ID: 22777737
[TBL] [Abstract][Full Text] [Related]
9. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
Front Immunol; 2019; 10():491. PubMed ID: 30936880
[TBL] [Abstract][Full Text] [Related]
10. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
11. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
12. Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.
Panda AK; Kim YH; Shevach EM
J Immunol; 2022 Feb; 208(4):851-860. PubMed ID: 35039334
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets.
Kim EJ; Lee JG; Kim JY; Song SH; Joo DJ; Huh KH; Kim MS; Kim BS; Kim YS
Immunology; 2017 Dec; 152(4):628-637. PubMed ID: 28758197
[TBL] [Abstract][Full Text] [Related]
14. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
15. Signaling triggered by glucocorticoid-induced tumor necrosis factor receptor family-related gene: regulation at the interface between regulatory T cells and immune effector cells.
Esparza EM; Arch RH
Front Biosci; 2006 May; 11():1448-65. PubMed ID: 16368528
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells: a potential target in cancer immunotherapy.
Shitara K; Nishikawa H
Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
[TBL] [Abstract][Full Text] [Related]
17. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
Madireddi S; Schabowsky RH; Srivastava AK; Sharma RK; Yolcu ES; Shirwan H
PLoS One; 2012; 7(8):e42459. PubMed ID: 22870329
[TBL] [Abstract][Full Text] [Related]
18. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
19. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
Nocentini G; Cari L; Ronchetti S; Riccardi C
Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
[TBL] [Abstract][Full Text] [Related]
20. Novel Foxp3(-) IL-10(-) Regulatory T-cells Induced by B-Cells Alleviate Intestinal Inflammation in Vivo.
Shao TY; Hsu LH; Chien CH; Chiang BL
Sci Rep; 2016 Sep; 6():32415. PubMed ID: 27581189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
